17th October 2023 | 2:30pm KST / 1:30pm CST / 11:00am IST / 7:30am CEST / 6:30am BST | Dr. Yaron Silberberg, Chief Scientist & Head of Customer Solution Center at Ajinomoto Genexine and Dr. Mehran Rafigh Global Director Sales and Marketing at Yokogawa |BOOK FREE SEAT FOR THIS WEBINAR
Cell culture media composition and upstream bioprocess conditions are crucial factors affecting protein yield in the production of biologics and biosimilars. Recently, advanced new techniques were developed that use IT approaches, including computer simulation of bioprocesses, AI tools and ‘multi-omics’ methods for analysis of cellular metabolic pathways. These techniques allow optimization of both process and media composition for maximizing culture performance and protein production. In my talk, I will discuss the importance of cell culture media optimization and feeding conditions for achieving the most out of biologics pipelines. I will also discuss about other supplements that can help achieve faster cell growth and higher productivity.
- DoE approaches for media formulation and feeding optimization
- ‘Digital Twins’ bio-simulations for reducing wet data requirements and allowing rapid optimization of feeding manner
- Multi-omics and metabolic flux analysis for identification of metabolic bottlenecks and critical media components, for development of enhanced basal and feed media
- Supplements for productivity enhancement
Presented by Dr. Yaron Silberberg, Chief Scientist & Head of Customer Solution Center at Ajinomoto Genexine
Yaron Silberberg completed his Ph.D. in Bio-Nanotechnology at University College London (UCL), in the field of cell biomechanics. He then moved to Japan to continue his research at Kyoto University and at the Advanced Institute for Science and Technology (AIST), as well as the MIT overseas campus in Singapore, working on the development of biosensors and nanoneedle bio-chips for drug and protein delivery, as well as microfluidic devices for in-vitro diagnostics (IVDs) of cancers. Following that, he joined the University of Tokyo in Japan as Associate Professor, teaching biotechnology courses and organizing student exchange programs with top global universities. In 2018, Yaron moved to Korea to join Ajinomoto Genexine Co., Ltd., where he is currently working as Chief Scientist and Head of the R&D and Customer Solutions Center, focusing on cell culture media development and process optimization for biotherapeutics production
Followed by a presentation on
Digital Twins in Bioprocessing: How To UnLock The Potential of Data in Process Development and Manufacturing
Dr. Rafigh explores the latest advances in digital twins for bioprocessing. Discover how digital twins will transform of the biomanufacturing landscape by enabling real-time monitoring, optimization, and predictive analytics and will provide an outlook on Yokogawa Insilico Biotechnology’s digital twin technology.
Presented by by Dr. Mehran Rafigh Global Director Sales and Marketing at Yokogawa
Dr. Mehran Rafigh has more than 15 years of experience in the biotech industry in various meagering roles in product management, marketing, sales and services . He currently serves as the Global Director of Sales, Product Management, and Services at Yokogawa Insilico Biotechnology, where he is responsible for sales and services, product management, and strategic marketing. Prior to this, he held several influential positions at Sartorius Stedim Biotech, including Global Head of Validation Services, Global Key Account Manager and M&A Manager. Dr. Rafigh also has experience as an Investment Manager at High-Tech Gründerfonds, Europe’s largest seed fund, where he focused on due diligence, venture capital, deal structuring, investments, and negotiations. He holds a PhD in Cell and Developmental Biology from The Research Institute of Molecular Pathology and an MBA in Business Administration from Open University Business School.
Sponsored by Yokogawa Insilico Biotechnology GmbH
Yokogawa Insilico Biotechnology GmbH specializes in developing and delivering predictive Digital Twins that advance biopharmaceutical process development and manufacturing. By leveraging artificial intelligence and biochemical networks, Insilico’s Digital Twins of cell culture processes provide superior productivity, product quality, and process robustness. This ground-breaking technology substantially reduces the need for experimental effort, cuts costs of goods, and accelerates time to market. As a result, leading biopharmaceutical companies worldwide rely on Insilico Digital Twins for cell line development, media design, and process control. Founded in 2001, Yokogawa Insilico Biotechnology GmbH, based in Stuttgart, Germany, is a subsidiary of Yokogawa Corporate Electric Corporation, headquartered in Tokyo, Japan.